[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BioTechVisions Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1885166346230784002.png) BioTech Visionary [@BioTechVisions](/creator/twitter/BioTechVisions) on x XX followers
Created: 2025-07-17 15:08:17 UTC

🛑 Novartis Stops ianalumab in Hidradenitis Suppurativa, But Eyes Autoimmune Boldly

Novartis has pulled the plug on ianalumab for hidradenitis suppurativa after its Phase X trial failed to meet efficacy benchmarks—despite showing some promise vs placebo. 🧪

But it’s not the end for this dual-action, B cell–depleting antibody. ianalumab is still on track in Phase X trials for Sjögren’s syndrome (data expected H2 2025), SLE, and systemic sclerosis, plus a program in immune thrombocytopenia.

Meanwhile, Novartis is pivoting its HS focus to remibrutinib, its BTK inhibitor, now heading into Phase X. Big shift—but a smart reallocation of resources to where the data is strongest.

#Novartis #Ianalumab #HS #Sjögrens #Autoimmune #AIDrugDev #ClinicalTrials

![](https://pbs.twimg.com/media/GwEYMnAWYAA7XBb.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945863131571642811/c:line.svg)

**Related Topics**
[plug](/topic/plug)
[novartis](/topic/novartis)
[$novnsw](/topic/$novnsw)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/BioTechVisions/status/1945863131571642811)